A Double-Blind, Randomised, Single Centre, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of a Single Subcutaneous Implant of EPT 1647 in Patients Suffering from Recurrent Polymorphous Light Eruption
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Afamelanotide (Primary)
 - Indications Polymorphus light eruptions
 - Focus Therapeutic Use
 - Acronyms EP012
 - Sponsors Clinuvel Pharmaceuticals
 
Most Recent Events
- 07 Jul 2016 New trial record